XENE analyst estimates
Xenon Pharmaceuticals (XENE) analyst ratings, the average price target and its range, and every firm's latest call.
XENE analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Sep 28, 2026 | Jefferies | Xenon Pharmaceuticals (XENE) PT Lowered to $90 at Jefferies | $90.00 |
| Sep 18, 2026 | Deutsche Bank | Deutsche Bank Downgrades Xenon Pharmaceuticals (XENE) to Hold | $46.00 |
| Sep 18, 2026 | Wells Fargo | Xenon Pharmaceuticals price target lowered to $64 from $69 at Wells Fargo | $64.00 |
| Sep 18, 2026 | Robert W. Baird | Xenon Pharmaceuticals price target lowered to $90 from $97 at Baird | $90.00 |
| Sep 18, 2026 | Needham | Xenon Pharmaceuticals price target lowered to $60 from $78 at Needham | $60.00 |
| Sep 18, 2026 | Wedbush | Xenon Pharmaceuticals price target lowered to $55 from $71 at Wedbush | $55.00 |
| Sep 18, 2026 | RBC Capital | Xenon Pharmaceuticals price target lowered to $70 from $81 at RBC Capital | $70.00 |
| Aug 10, 2026 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on Xenon Pharmaceuticals (XENE) | $74.00 |
| Aug 7, 2026 | RBC Capital | Xenon Pharmaceuticals price target lowered to $81 from $82 at RBC Capital | $81.00 |
| May 10, 2026 | Wells Fargo | Xenon Pharmaceuticals price target raised to $69 from $68 at Wells Fargo | $69.00 |
| May 8, 2026 | Needham | Xenon Pharmaceuticals price target lowered to $78 from $80 at Needham | $78.00 |
| Mar 10, 2026 | Deutsche Bank | Xenon Pharmaceuticals price target raised to $90 from $56 at Deutsche Bank | $90.00 |
| Mar 9, 2026 | Guggenheim | Xenon Pharmaceuticals (XENE) PT Raised to $90 at Guggenheim | $90.00 |
| Mar 9, 2026 | Jefferies | Xenon Pharmaceuticals (XENE) PT Raised to $100 at Jefferies | $100.00 |
| Mar 9, 2026 | RBC Capital | Xenon Pharmaceuticals price target raised to $80 from $59 at RBC Capital | $80.00 |
- 9 firms rate XENE: 8 buy, 1 hold, 0 sell.
- The average price target is $68.62 from 8 analysts, from $46.00 to $90.00.
Updated 2026-11-02 23:59 UTC